20-54171651-G-A
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_ModerateBS2
The NM_000782.5(CYP24A1):c.469C>T(p.Arg157Trp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00276 in 1,613,766 control chromosomes in the GnomAD database, including 11 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. R157R) has been classified as Benign.
Frequency
Consequence
NM_000782.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CYP24A1 | NM_000782.5 | c.469C>T | p.Arg157Trp | missense_variant | 3/12 | ENST00000216862.8 | NP_000773.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CYP24A1 | ENST00000216862.8 | c.469C>T | p.Arg157Trp | missense_variant | 3/12 | 1 | NM_000782.5 | ENSP00000216862 | P1 | |
CYP24A1 | ENST00000395955.7 | c.469C>T | p.Arg157Trp | missense_variant | 3/11 | 1 | ENSP00000379285 | |||
CYP24A1 | ENST00000395954.3 | c.43C>T | p.Arg15Trp | missense_variant | 1/10 | 1 | ENSP00000379284 |
Frequencies
GnomAD3 genomes AF: 0.00178 AC: 271AN: 151980Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00184 AC: 463AN: 251288Hom.: 0 AF XY: 0.00181 AC XY: 246AN XY: 135810
GnomAD4 exome AF: 0.00286 AC: 4187AN: 1461668Hom.: 11 Cov.: 33 AF XY: 0.00277 AC XY: 2017AN XY: 727146
GnomAD4 genome AF: 0.00178 AC: 271AN: 152098Hom.: 0 Cov.: 32 AF XY: 0.00149 AC XY: 111AN XY: 74360
ClinVar
Submissions by phenotype
not provided Uncertain:3Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 25, 2024 | - - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Aug 01, 2023 | CYP24A1: BP4 - |
Uncertain significance, criteria provided, single submitter | clinical testing | Molecular Diagnostics Lab, Nemours Children's Health, Delaware | Aug 25, 2014 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Feb 02, 2016 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Dec 12, 2022 | Identified in individuals with hypercalcemia or hypercalcuria in the literature but it is unknown whether they were screened for variants in other genes associated with hypercalcemia (Figueres et al., 2015; Trutin et al., 2022); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 23293122, 34426522, 34307984, 34805638, 35282483, 25446019) - |
Hypercalcemia, infantile, 1 Uncertain:4
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Oct 24, 2023 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Molecular Genetics Laboratory, Biocruces Bizkaia Health Research Institute | Mar 08, 2024 | - - |
CYP24A1-related disorder Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 06, 2023 | The CYP24A1 c.469C>T variant is predicted to result in the amino acid substitution p.Arg157Trp. This variant was reported in at least four individuals with hypercalcemia and/or kidney stones along with a second potentially causative variant (Figueres. 2015. PubMed ID: 25446019; Hanna. 2021. PubMed ID: 34307984; Cogal. 2021. PubMed ID: 34805638), and in one individual with kidney stones without a second variant (Trutin. 2022. PubMed ID: 35282483). This variant is reported in 0.33% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/20-52788190-G-A). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at